Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Chief Medical Officer | November 01, 2025 | November 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date November 01, 2025 · Filed November 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,568 |
Reported balance
After 2025-11-01 transaction · row 1
1 source rowRow 1 · 2025-11-01 · Tax withholding · Disposed 4,588 · Balance 146,568 F2: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,762 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. |
Filing footnotes · ownership attribution and instrument terms
F2: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,762 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2025 Filed Nov 4, 2025 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 4,588 | $0.43 | $1,991.19 |
DisclosureSEC source: 0001477932-25-007902 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,568 F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,762 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 19,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006099 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,156 F1 · shares: On August 15, 2025, the reporting person was awarded 19,524 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two equal installments of 9,762 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 6,142 | $0.64 | $3,930.88 |
DisclosureSEC source: 0001477932-25-005473 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,632 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,069 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 17:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 4,401 | $0.77 | $3,379.53 |
DisclosureSEC source: 0001477932-25-004912 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,774 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,365 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 4,598 | $0.50 | $2,312.79 |
DisclosureSEC source: 0001477932-25-004368 · form4.xml · nonDerivative · entry 2 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,175 F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,784 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-004368 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,773 F1 · shares: On June 1, 2025, the reporting person was awarded 13,069 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,357 units, 4,356 units, and 4,356 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:06 UTC | VOLITIONRX LTD VRNX · Entity 8241 | Tax withholdingCommon Stock | 3,913 | $0.49 | $1,907.59 |
DisclosureSEC source: 0001477932-25-003319 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,704 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 8,326 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 10,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-001460 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,617 F1 · shares: On March 1, 2025, the reporting person was awarded 10,142 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,381 units, 3,381 units, and 3,380 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 9,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-007800 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,475 F1 · shares: On December 1, 2024, the reporting person was awarded 9,365 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,122 units, 3,122 units, and 3,121 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 9,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005501 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,110 F1 · shares: On September 1, 2024, the reporting person was awarded 9,784 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,262 units, 3,261 units, and 3,261 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 8,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003489 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,326 F1 · shares: On June 1, 2024, the reporting person was awarded 8,326 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 2,776 units, 2,775 units, and 2,775 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003295 · form4.xml · nonDerivative · entry 1 Retter Andrew · CIK 0002015252 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: In connection with his employment as Chief Medical Officer of Volition Diagnostics UK Limited, Dr. Retter received restricted stock units ("RSUs") subject to a 3-year vesting schedule, vesting as to 33,334 units, 33,333 units, and 33,333 units on each of May 23, 2025, May 23, 2026 and May 23, 2027, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.